The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•29 April 2026•

1 min read

FDA Grants Priority Review for Gilead's Once-Daily HIV Treatment Combination

Key Facts

1The U.S. FDA accepted the New Drug Application for Gilead Sciences' bictegravir and lenacapavir combination regimen.

2The agency granted priority review for the application and assigned a PDUFA action date in August.

Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application for its combination regimen of bictegravir and lenacapavir. The agency granted priority review for the treatment, which is designed as a once-daily single-tablet for virologically suppressed adults living with HIV. This designation is intended to accelerate the evaluation of therapies that offer significant improvements over existing treatments for serious conditions. The FDA has assigned a PDUFA action date in August to conclude its review process. This development serves as a positive catalyst for Gilead, strengthening its core therapeutic portfolio in the biotechnology sector. Investors are closely monitoring the outcome, as approval could streamline treatment options for a significant patient population.